Ana Carrizosa Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Carrizosa Anderson has a total of 402 co-authors. Here are the top co-authors by number of shared publications:
- Vijay K. Kuchroo
Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital and Harvard Medical School and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA
11 shared publications - Aviv Regev
Department of Biology, Massachusetts Institute of Technology, Cambridge, USA
9 shared publications Nandini Acharya
Gene Lay Institute of Immunology and Inflammation, Harvard Medical School and Mass General Brigham, Boston, MA 02115 USA
8 shared publicationsGiulia Escobar
Gene Lay Institute of Immunology and Inflammation, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Mass General Brigham, Boston, MA 02115, USA
6 shared publicationsDavide Mangani
Gene Lay Institute of Immunology and Inflammation, Harvard Medical School and Mass General Brigham, Boston, MA 02115 USA
5 shared publications- Davide Mangani
Institute for Research in Biomedicine, Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland
5 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-12
Insights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas of colorectal cancer across the age continuum
- 29 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-12
Open AccessInsights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas of colorectal cancer across the age continuum
- Open Access
A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eaeb8333
Loss-of-function mutations ensure that response to immune checkpoint therapy is NOD2 be denied
Loss-of-function mutations in NOD2 may predict positive response to PD-1 blockade monotherapy in cancer.
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eaeb8333
Loss-of-function mutations ensure that response to immune checkpoint therapy is NOD2 be denied
Loss-of-function mutations in NOD2 may predict positive response to PD-1 blockade monotherapy in cancer.
- Open Access
- 8 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011652
Therapeutic potential of targeting LAG-3 in cancer
Immune checkpoint inhibitors targeting negative regulatory checkpoints including programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have produced significant improvements in progression-free survival (PFS) and overall survival in multiple solid tumors. Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly expressed by exhausted T cells. Dual blockade of LAG-3 and PD-1 with monoclonal antibodies relatlimab and nivolumab has improved PFS in advanced melanoma, leading to Food and Drug Administration approval for this indication. Concurrently, enthusiasm for targeting LAG-3 has been tempered by negative results in multiple indications, although novel approaches including LAG-3-directed bispecifics tebotelimab continue to demonstrate promise. In this review, we discuss the current understanding of LAG-3 in regulating antitumor immunity and the ongoing state of clinical development of LAG-3-directed agents in cancer.
- 8 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011652
Open AccessTherapeutic potential of targeting LAG-3 in cancer
Immune checkpoint inhibitors targeting negative regulatory checkpoints including programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have produced significant improvements in progression-free survival (PFS) and overall survival in multiple solid tumors. Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly expressed by exhausted T cells. Dual blockade of LAG-3 and PD-1 with monoclonal antibodies relatlimab and nivolumab has improved PFS in advanced melanoma, leading to Food and Drug Administration approval for this indication. Concurrently, enthusiasm for targeting LAG-3 has been tempered by negative results in multiple indications, although novel approaches including LAG-3-directed bispecifics tebotelimab continue to demonstrate promise. In this review, we discuss the current understanding of LAG-3 in regulating antitumor immunity and the ongoing state of clinical development of LAG-3-directed agents in cancer.
- Open Access
- 2 July 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (7) , 101640
Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity
- 2 July 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (7) , 101640
Open AccessPan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity
- Open Access
- 24 June 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (5) , 911-922
Dietary protein modulates intestinal dendritic cells to establish mucosal homeostasis
- 24 June 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (5) , 911-922
Open AccessDietary protein modulates intestinal dendritic cells to establish mucosal homeostasis
- Top Cited PapersOpen Access
- 19 June 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (6) , e009063
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antigen receptor-T cell therapies specific for two targets, and two distinct classes of bispecific T cell engagers, a vaccine, and an oncolytic virus have joined cytokines as a standard of cancer care. At the same time, scientific progress has delivered vast amounts of new knowledge. For example, advances in technologies such as single-cell sequencing and spatial transcriptomics have provided deep insights into the immunobiology of the tumor microenvironment. With this rapid clinical and scientific progress, the field of cancer immunotherapy is currently at a critical inflection point, with potential for exponential growth over the next decade. Recognizing this, the Society for Immunotherapy of Cancer convened a diverse group of experts in cancer immunotherapy representing academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community to identify current opportunities and challenges with the goal of prioritizing areas with the highest potential for clinical impact. The consensus group identified seven high-priority areas of current opportunity for the field: mechanisms of antitumor activity and toxicity; mechanisms of drug resistance; biomarkers and biospecimens; unique aspects of novel therapeutics; host and environmental interactions; premalignant immunity, immune interception, and immunoprevention; and clinical trial design, endpoints, and conduct. Additionally, potential roadblocks to progress were discussed, and several topics were identified as cross-cutting tools for optimization, each with potential to impact multiple scientific priority areas. These cross-cutting tools include preclinical models, data curation and sharing, biopsies and biospecimens, diversification of funding sources, definitions and standards, and patient engagement. Finally, three key guiding principles were identified that will both optimize and maximize progress in the field. These include engaging the patient community; cultivating diversity, equity, inclusion, and accessibility; and leveraging the power of artificial intelligence to accelerate progress. Here, we present the outcomes of these discussions as a strategic vision to galvanize the field for the next decade of exponential progress in cancer immunotherapy.
- 19 June 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (6) , e009063
Top Cited PapersOpen AccessChallenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antigen receptor-T cell therapies specific for two targets, and two distinct classes of bispecific T cell engagers, a vaccine, and an oncolytic virus have joined cytokines as a standard of cancer care. At the same time, scientific progress has delivered vast amounts of new knowledge. For example, advances in technologies such as single-cell sequencing and spatial transcriptomics have provided deep insights into the immunobiology of the tumor microenvironment. With this rapid clinical and scientific progress, the field of cancer immunotherapy is currently at a critical inflection point, with potential for exponential growth over the next decade. Recognizing this, the Society for Immunotherapy of Cancer convened a diverse group of experts in cancer immunotherapy representing academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community to identify current opportunities and challenges with the goal of prioritizing areas with the highest potential for clinical impact. The consensus group identified seven high-priority areas of current opportunity for the field: mechanisms of antitumor activity and toxicity; mechanisms of drug resistance; biomarkers and biospecimens; unique aspects of novel therapeutics; host and environmental interactions; premalignant immunity, immune interception, and immunoprevention; and clinical trial design, endpoints, and conduct. Additionally, potential roadblocks to progress were discussed, and several topics were identified as cross-cutting tools for optimization, each with potential to impact multiple scientific priority areas. These cross-cutting tools include preclinical models, data curation and sharing, biopsies and biospecimens, diversification of funding sources, definitions and standards, and patient engagement. Finally, three key guiding principles were identified that will both optimize and maximize progress in the field. These include engaging the patient community; cultivating diversity, equity, inclusion, and accessibility; and leveraging the power of artificial intelligence to accelerate progress. Here, we present the outcomes of these discussions as a strategic vision to galvanize the field for the next decade of exponential progress in cancer immunotherapy.
- Top Cited Papers
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation